Sheryar Siddiq
Fri, January 2, 2026 astatine 9:50 AM CST 2 min read
By the extremity of 2028, Roivant’s “Next 36 Month vision” anticipates astatine slightest 3 commercialized launches, 4 oregon much NDA/BLA submissions, nary little than 8 important readouts, and astatine slightest 3 proof-of-concept evaluations.
Roivant Sciences Ltd. (NASDAQ:ROIV) has besides precocious the improvement schedules for its superior therapeutic candidates, including brepocitinib, with a New Drug Application filing for dermatomyositis slated successful aboriginal 2026 on with a imaginable commercialized motorboat successful aboriginal 2027. Furthermore, the Phase III proceedings for brepocitinib successful non-infectious uveitis has reached afloat enrollment up of time, with topline results expected successful the 2nd fractional of 2026.
Roivant Sciences Ltd. (NASDAQ:ROIV) is simply a clinical-stage biopharmaceutical institution that discovers, develops, and commercializes medicines and technologies. Its objective merchandise candidates see IMVT-1402, an antibody that targets the neonatal Fc receptor for the attraction of Graves’ illness and difficult-to-treat rheumatoid arthritis.
While we admit the imaginable of ROIV arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. This nonfiction is primitively published at Insider Monkey.

1 week ago
9





English (CA) ·
English (US) ·
Spanish (MX) ·